Bioxytran, Inc (BIXT) stock
Close on Oct 19, 2026Market cap $2.56MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $2.56M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$3.49M
- EPS, diluted
- -$0.04
- Book value per share
- -$0.04
- Diluted shares
- 114M
Trading
- Previous close
- $0.02
- Open
- $0.02
- Day's range
- $0.02 – $0.02
- Volume
- 5,508
- Average volume (20 days)
- 72,681
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | BIXT | S&P 500 | Difference | BIXT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +4.6% | +0.6% | +4.0 pts | ||
| 3 months | -12.6% | +3.4% | −16.0 pts | ||
| Year to date | -70.5% | +13.3% | −83.8 pts | ||
| 1 year | -65.8% | +16.6% | −82.4 pts | ||
| 3 years | -86.8% | +86.4% | −173.2 pts | -49.1% | +23.1% |
| 5 years | +917.3% | +81.9% | +835.4 pts | +59.0% | +12.7% |
| 10 years | -98.5% | +318.9% | −417.4 pts | -34.3% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases Bioxytran filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- News
About Bioxytran
Pharmaceutical Preparations
Bioxytran, Inc. is a clinical-stage pharmaceutical company focused on developing platform technologies in glycovirology, hypoxia, and degenerative diseases. Utilizing carbohydrate drug design and Galectin inhibitors, the company works to eliminate viruses such as SARS-CoV-2 and address conditions associated with cellular degeneration and inflammation. Its operational structure includes specialized subsidiaries dedicated to viral disease therapeutics, prototyping manufacturing equipment, developing partially hydrolyzed guar gum derivatives, and safeguarding intellectual property.
Company profile, executives and historyBioxytran stock: common questions
What is Bioxytran's stock price?
BIXT closed at $0.02 on Oct 19, 2026, down 3.95% on the day.
What is Bioxytran's market cap?
Bioxytran was worth $2.56M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is BIXT's P/E ratio?
Bioxytran lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.04), so it has no meaningful P/E ratio.
Does Bioxytran pay a dividend?
No. Bioxytran has not paid a cash dividend over the last twelve months.
How has BIXT stock performed over the past year?
Including dividends, BIXT returned -65.8% over the past year, against +16.6% for the S&P 500.
Who are Bioxytran's competitors?
Companies most similar to Bioxytran by business, industry and size include VICP, ANTX, RANI, DCOY, HIND.
See a number that looks wrong?